Tourmaline Bio Inc. (TRML) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tourmaline Bio Inc. (TRML) has a cash flow conversion efficiency ratio of -0.078x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.26 Million) by net assets ($259.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TRML net asset quality index to measure how much of total assets are equity-financed.
Tourmaline Bio Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Tourmaline Bio Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Tourmaline Bio Inc.'s earnings quality to evaluate the quality of earnings relative to operating cash generation.
Tourmaline Bio Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tourmaline Bio Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Techno Electric & Engineering Company Limited
NSE:TECHNOE
|
-0.042x |
|
Grupo Televisa S.A.B.
F:TLV
|
0.100x |
|
Biotage AB
ST:BIOT
|
0.011x |
|
Treehouse Foods Inc
NYSE:THS
|
0.030x |
|
COSMO Pharmaceuticals SA
LSE:0RGI
|
0.002x |
|
WHA Premium Growth Freehold And Leasehold Real Estate Investment Trust
BK:WHART
|
-0.001x |
|
Guizhou Broadcasting&TV Info
SHG:600996
|
0.053x |
|
Tessenderlo
BR:TESB
|
0.057x |
Annual Cash Flow Conversion Efficiency for Tourmaline Bio Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Tourmaline Bio Inc. from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Tourmaline Bio Inc. stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $300.05 Million | $-77.26 Million | -0.257x | -88.02% |
| 2023-12-31 | $205.04 Million | $-28.08 Million | -0.137x | -141.84% |
| 2022-12-31 | $-19.73 Million | $-6.46 Million | 0.327x | +298.73% |
| 2021-12-31 | $242.81 Million | $-39.99 Million | -0.165x | -26.87% |
| 2020-12-31 | $148.00 Million | $-19.21 Million | -0.130x | +70.90% |
| 2019-12-31 | $39.59 Million | $-17.66 Million | -0.446x | -- |
About Tourmaline Bio Inc.
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline c… Read more